VISTAGEN THERAPEUTICS INC (VTGN) Stock Price, Quote, News and Overview
NASDAQ:VTGN - Nasdaq - US92840H4002 - Common Stock - Currency: USD
VTGN Quote, Performance and Key Statistics
NASDAQ:VTGN (3/6/2025, 8:10:28 PM)
2.67
-0.03 (-1.11%)
The current stock price of VTGN is 2.67 USD. In the past month the price decreased by -9.49%. In the past year, price decreased by -36.58%.
VTGN Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.83 | 372.42B | ||
| AMGN | AMGEN INC | 16.04 | 170.67B | ||
| GILD | GILEAD SCIENCES INC | 25.17 | 144.59B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1674.9 | 124.78B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.3 | 76.35B | ||
| ARGX | ARGENX SE - ADR | 238.59 | 37.26B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.00B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.42B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.57B | ||
| BIIB | BIOGEN INC | 8.95 | 21.47B | ||
| NTRA | NATERA INC | N/A | 18.68B | ||
| GMAB | GENMAB A/S -SP ADR | 24.96 | 15.06B |
Related stock screener links
About VTGN
Company Profile
VistaGen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in developing and commercializing medication and treatment for anxiety, depression, and other central nervous system disorders. The company is headquartered in South San Francisco, California and currently employs 45 full-time employees. The company went IPO on 2010-10-18. The firm is engaged in the development and commercialization of therapies for psychiatric and neurological disorders based on its understanding of nose-to-brain neurocircuitry. Its clinical-stage pipeline consists of intranasal product candidates from a new class of potential neuroscience therapies called pherines. Its diversified pipeline of pherine product candidates rapidly activate chemosensory neurons in the nasal cavity to impact fundamental neurocircuitry in the olfactory system and the brain. Its pipeline also includes an oral prodrug with potential to modulate N-methyl-D-aspartate receptor (NMDA) receptor activity. Its neuroscience pipeline includes five clinical-stage investigational agent, namely Fasedienol (PH94B), Itruvone (PH10), AV-101, PH15, PH80, and PH284.
Company Info
VISTAGEN THERAPEUTICS INC
343 Allerton Avenue
South San Francisco CALIFORNIA 94080 US
CEO: Shawn K. Singh
Employees: 41
Company Website: https://www.vistagen.com/
Investor Relations: https://www.vistagen.com/investors/overview
Phone: 16505773600
VISTAGEN THERAPEUTICS INC / VTGN FAQ
What is the stock price of VISTAGEN THERAPEUTICS INC today?
The current stock price of VTGN is 2.67 USD. The price decreased by -1.11% in the last trading session.
What is the ticker symbol for VISTAGEN THERAPEUTICS INC stock?
The exchange symbol of VISTAGEN THERAPEUTICS INC is VTGN and it is listed on the Nasdaq exchange.
On which exchange is VTGN stock listed?
VTGN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for VISTAGEN THERAPEUTICS INC stock?
10 analysts have analysed VTGN and the average price target is 13.26 USD. This implies a price increase of 396.63% is expected in the next year compared to the current price of 2.67. Check the VISTAGEN THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is VISTAGEN THERAPEUTICS INC worth?
VISTAGEN THERAPEUTICS INC (VTGN) has a market capitalization of 74.33M USD. This makes VTGN a Micro Cap stock.
How many employees does VISTAGEN THERAPEUTICS INC have?
VISTAGEN THERAPEUTICS INC (VTGN) currently has 41 employees.
What are the support and resistance levels for VISTAGEN THERAPEUTICS INC (VTGN) stock?
VISTAGEN THERAPEUTICS INC (VTGN) has a support level at 2.56 and a resistance level at 2.8. Check the full technical report for a detailed analysis of VTGN support and resistance levels.
Is VISTAGEN THERAPEUTICS INC (VTGN) expected to grow?
The Revenue of VISTAGEN THERAPEUTICS INC (VTGN) is expected to decline by -43.51% in the next year. Check the estimates tab for more information on the VTGN EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy VISTAGEN THERAPEUTICS INC (VTGN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of VTGN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of VTGN, evaluating the profitability, health, valuation and growth aspects
- VISTAGEN THERAPEUTICS INC (VTGN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- VISTAGEN THERAPEUTICS INC (VTGN) Sales and EPS estimates to see what analysts future expectations are.
- VISTAGEN THERAPEUTICS INC (VTGN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- VISTAGEN THERAPEUTICS INC (VTGN) Insider and Institutional Ownership to learn about the owners and their transactions.
- VISTAGEN THERAPEUTICS INC (VTGN) Stock Chart to make your own analysis
- VISTAGEN THERAPEUTICS INC (VTGN) Latest news and press-releases to stay up to date.
Does VISTAGEN THERAPEUTICS INC (VTGN) stock pay dividends?
VTGN does not pay a dividend.
When does VISTAGEN THERAPEUTICS INC (VTGN) report earnings?
VISTAGEN THERAPEUTICS INC (VTGN) will report earnings on 2025-06-09, after the market close.
What is the Price/Earnings (PE) ratio of VISTAGEN THERAPEUTICS INC (VTGN)?
VISTAGEN THERAPEUTICS INC (VTGN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.48).
What is the Short Interest ratio of VISTAGEN THERAPEUTICS INC (VTGN) stock?
The outstanding short interest for VISTAGEN THERAPEUTICS INC (VTGN) is 2.41% of its float. Check the ownership tab for more information on the VTGN short interest.
VTGN Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to VTGN. When comparing the yearly performance of all stocks, VTGN is a bad performer in the overall market: 78.49% of all stocks are doing better.
VTGN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to VTGN. While VTGN has a great health rating, there are worries on its profitability.
VTGN Financial Highlights
Over the last trailing twelve months VTGN reported a non-GAAP Earnings per Share(EPS) of -1.48. The EPS increased by 56.81% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -51.25% | ||
| ROE | -58.31% | ||
| Debt/Equity | 0 |
VTGN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 88% to VTGN. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of -10.64% and a revenue growth -43.51% for VTGN